Table 2.
SPARC expression in the primary tumor
| High SPARC | Low SPARC | No SPARC | |
|---|---|---|---|
| Histology | N = 22 | N = 13 | N = 15 |
| UPS | 16 | 9 | 7 |
| LMS | 2 | 2 | 2 |
| LPS | 3 | 1 | 2 |
| Dedifferentiated | 2 | 1 | 0 |
| Pleomorphic/NOS | 1 | 0 | 1 |
| Myxoid | 0 | 0 | 1 |
| SS | 0 | 0 | 3 |
| MPNST | 0 | 1 | 1 |
| FS | 1 | 0 | 0 |
| Treatment for primary prior to tumor collection | |||
| Gemcitabine/docetaxel | 14 | 3 | 3 |
| Doxorubicin/ifosfamide | 5 | 9 | 10 |
| None | 3 | 1 | 3 |
| Radiation | 0 | 1 | 1 |
| % necrosis observed in tumor after chemotherapy | |||
| UPS | 20–100 | 0–70 | 0–75 |
| LMS | 50 | 80a | 30 |
| LPS | |||
| Dedifferentiated | 15–50 | 0 | NA |
| Pleomorphic/NOS | 85 | NA | 10 |
| Myxoid | NA | NA | 90 |
| SS | NA | NA | 0–80a |
| MPNST | NA | 5 | 40 |
| FS | 10 | NA | NA |
| Best Response to chemotherapy by RECIST 1.0 | |||
| Partial response | 0 | 2 | 0 |
| Stable disease | 19 | 8 | 14 |
| Progressive disease | 3 | 3 | 1 |
| Recurrence | 9 | 7 | 5 |
| Local | 2 | 4 | 0 |
| Distant | 7 | 3 | 5 |
aPt with 80 % necrosis had prior radiation